215 results about "Protein markers" patented technology

The present invention relates to methods of detecting renal transplant rejection and other forms of renal damage. Protein markers or renal damage are provided, along with assays for detecting said markers. Also provided are methods for identifying markers of renal damage.

Processes and materials are provided for the detection, diagnosis, or determination of the severity of a neurological injury or condition, including traumatic brain injury, multiple-organ injury, stroke, Alzeimer's disease, Pakinson disease and Chronic Traumatic Encephalopathy (CTE). The processes and materials include biomarkers detected or measured in a biological sample such as whole blood, serum, plasma, or CSF. Such biomarkers include Tau and GFAP proteins, their proteolytic breakdown products, brain specific or enriched micro-RNA, and brain specific or enriched protein directed autoantibodies. The processes and materials are operable to detect the presence of absence of acute, subacute or chronic brain injuries and predict outcome for the brain injury.

An improved method for protein labeling comprising the steps of providing a synthetic small molecule tag, providing a target protein to be tagged, providing at least two enzymes for catalyzing a conjugation reaction between the tag and the target protein, incubating the tag, the protein and the enzyme, and allowing the tag to conjugate to the target protein. The tag may embody at least one structural feature of an ubiquitin C-terminus, and the structural feature may comprise a recognition sequence that is recognizable by an ubiquitin activating enzyme.

The invention discloses a male multi-tumor marker detection protein chip and a kit thereof. The chip comprises a substrate, protein markers distributed in an array type and point coatings of contrasts, wherein the substrate is a glass substrate or a film substrate; and the tumor markers and the point coatings of the contrasts are seven protein markers of AFP, CEA, NSE, CYFRA21-1, CA19-9, tPSA and SCC-ag, a positive contrast and a negative contrast which are uniformly distributed and latticed on the substrate. A reaction result of various indexes can be obtained only through one reaction by utilizing the protein chip, and the following tumors can be simultaneously screened: primary liver cancer, prostatic cancer, pancreatic cancer, lung cancer, esophageal cancer, gastric cancer and colorectal cancer. The invention is particularly suitable for the general examination of malignant tumors of male asymptomatic groups and high risk groups.

The invention discloses a self-immunity hepatitis detection protein chip and a kit thereof. The chip and the kit can be used for simultaneously detecting 12 immunity protein markers: ANA (dsDNA, RNP, Sm, SS-A/Ro, SS-B/La, Sc1-70, Jo-1), SMA, LKM-1, SLA/LP, F-actin and AMA. The invention overcomes the shortcomings of the current products that the detection index is single and incomplete. The invention provides a detection method which has a complete diction result and a simpler process.

A method for labeling acyl carrier protein (ACP) fusion proteins with a wide variety of different labels is disclosed. The method relies on the transfer of a label from a coenzyme A type substrate to an ACP fusion protein using a holo-acyl carrier protein synthase (ACPS) or a homologue thereof. The method allows detecting and manipulating the fusion protein, both in vitro and in vivo, by attaching molecules to the fusion proteins that introduce a new physical or chemical property to the fusion protein. Examples of such labels are, among others, spectroscopic probes or reporter molecules, affinity tags, molecules generating reactive radicals, cross-linkers, ligands mediating protein-protein interactions or molecules suitable for the immobilization of the fusion protein.

The present invention relates to protein markers for diagnosing stomach cancer and a diagnostic kit using the same, more precisely protein markers screened by two-dimensional gel electrophoresis and bioinformatics and a diagnostic kit using the same. The markers of the invention can be effectively used for diagnosing stomach cancer and evaluating the extent of progress of the cancer by confirming the expression levels of those marker proteins whose expressions differ in stomach cancer patients from in normal healthy people.

A method for predicting with high specificity from RTPCR detected markers if a patent is likely to respond to docetaxel treatment is disclosed. RTPCR detects the presence of absence of certain mutations due to fusion events. Together, with other protein markers, additional stratification is possible to identify patents suited for docetaxel therapy as opposed to for alternative treatments.

The invention relates to prognostic markers and prognostic signatures, and compositions and methods for determining the prognosis of cancer in a patient, particularly for melanoma. Specifically, the invention relates to the use of genetic and protein markers for the prediction of the risk of progression of a cancer, such as melanoma, based on markers and signatures of markers. In various aspects, the invention provides methods, compositions, kits, and devices based on prognostic cancer markers, specifically melanoma prognostic markers, to aid in the prognosis and treatment of cancer.

The present invention demonstrates that the diagnosis and prediction of clinical behavior in patients with hematologic malignancies, such as leukemia, can be accomplished by analysis of proteins present in a plasma sample. Thus, in particular embodiments the present invention uses plasma to create a diagnostic or prognostic protein profile of a hematologic malignancy comprising collecting plasma samples from a population of patients with hematologic malignancies; generating protein spectra from the plasma samples with or without fractionation; comparing the protein spectra with clinical data; and identifying protein markers in the plasma samples that correlate with the clinical data. Protein markers identified by this approach can then be used to create a protein profile that can be used to diagnose the hematologic malignancy or determine the prognosis of the hematologic malignancy. Potentially these specific proteins can be identified and targeted in the therapy of these malignancies.

The invention relates to a diagnostic kit for detecting a peripheral blood protein marker of an Alzheimer disease and a detection method using the diagnostic kit and belongs to the technical field of in vitro diagnosis detection. The detection method is characterized in that various protein markers in a same sample can be detected at one time, namely, a tetrad compound 'biotin-labeled detection antibody-Alzheimer disease protein marker-capture antibody-microsphere' is formed in the manner of preparation of a liquid chip, and fluorescence signals of different microspheres can be detected after the tetrad compound is combined with streptavidin-phycoerythrin, so that the existence and content of various protein markers related to the Alzheimer disease in a to-be-detected sample can be confirmed. The invention also discloses the components forming the diagnostic kit. The method and the kit provided by the invention have the advantages of high sensitivity, high throughput, high detection speed, accuracy, and the like, and can be used for simultaneously performing qualitative and quantitative detection on various protein markers related to the Alzheimer disease.

The present invention relates to an accurate, sensitive, and efficient sequential or concurrently sequential method for molecular diagnosis of human papillomavirus (HPV)-based disease, where the method improves the accuracy and reliability of diagnostic and prognostic assessments of HPV-based disease. The method of the invention comprises a primary screen of a sample for HPV nucleic acids, followed by a secondary screen for molecular markers, such as proliferation and cell cycle control group protein markers. The sequential or concurrently sequential method significantly reduces the number of false positive results.

The invention relates to application of protein and proteome in preparation of a liver cirrhosis diagnostic reagent. The protein comprises Lumican, Tetranectin, Pro-platelet basic protein (PBP), Pigment epithelium-derived factor (PEDF), Insulin-like growth factor binding protein 3 (IGFbp-3), Sex hormone-binding globulin (SHBG), Thioredoxin and composition of parts in the liver cirrhosis diagnostic reagent. Multiple proteins related with health and disease states are identified and evaluated in large range by adopting a proteome technology, the screened biomarkers for identifying hepatitis and liver fibrosis are used for predicting the degree of hepatitis and liver fibrosis and can be used for preparing a kit for diagnosing liver cirrhosis and liver cirrhosis level, and the protein markers identify the sensitivity of liver cirrhosis and degree thereof; and by combining the optimal conditions of various protein markers, the sensitivity can reach 89 percent, the specificity reaches over 90 percent, and the sensitivity and the specificity are higher than those of any known detection method.

The invention relates to a method and a device for detecting free epithelial cell organ sources in blood. The method includes the following steps: capturing epithelial cells from a blood sample; cracking the epithelial cells to release protein therein; specifically recognizing at least four protein markers with organ specificity; acquiring the organ sources of the epithelial cells by detecting expression quantity of the protein markers. The device comprises a microgroove chip and an antibody loading glass piece, 100-10000 microgrooves are formed in the microgroove chip and used for containing the cells, the antibody loading glass piece is used for loading an antibody micro-array which comprises at least four mutually-independent antibody strips, and the microgrooves and the antibody micro-array are arranged in a matched manner to enable at least one part of each antibody strip to be contained at corresponding positions of the microgrooves. The problem of detecting the epithelial cell organ sources in blood is solved by quickly and effectively detecting multiple proteins in single cells.

The invention discloses the use of an agent for detecting microRNA in exosomes in the preparation of a product for judging the presence and/or degree of cerebral ischemic injury, and relates to a method for early discrimination of a subject suffering from cardiogenic ischemic stroke and non-cardiogenic ischemic stroke. The method uses the exosomes in high-molecular polymer precipitate serum and areal-time fluorescence quantitative PCR technology, and experimental results show that the specificity and sensitivity of miR-155-5p and miR-93-5p are significantly higher than existing protein markers. Meanwhile, miR-133a-3p and miR-208a-3p expression of the exosomes of patients with cardiogenic ischemic stroke is significantly higher compared with patients with non-cardiogenic ischemic stroke under the condition of no significant changes in the serum miR-133a-3p and miR-208a-3p at the early stage so that the agent can be used as a marker to distinguish the cardiogenic ischemic stroke and thenon-cardiogenic ischemic stroke.

The invention discloses a joint detection method for heart cerebrovascular disease-related protein markers and a diagnostic kit thereof. A joint parallel detection method is characterized in that: a plurality of protein markers of the same sample can be detected at one time, i.e., a quadruple complex consisting of a signal marking detection antibody, a heart cerebrovascular disease-related protein marker, a capture antibody and microspheres is formed by preparing a liquid-phase chip, and the presence and content of various different heart cerebrovascular disease-related protein markers in a sample to be detected are determined by detecting marking signals of different microspheres in the quadruple complex. The invention further discloses constituents of the diagnostic kit and application of the diagnostic kit. The method and the kit provided by the invention have the outstanding advantages of high flux, high sensitivity, high specificity, quick and accurate detection and the like, and can be used for qualitatively and quantitatively detecting a plurality of heart cerebrovascular disease-related protein markers simultaneously.

The invention relates to a protein chip, a protein chip diagnostic kit, a preparation method and a using method. The protein chip contains the following protein markers of autologous antigen protein: a P53 antigen fragment, an SOX2 antigen fragment, a COPB1 antigen fragment, an EFHD2 antigen fragment, an EIF4G3 antigen fragment and a PCNA antigen fragment, wherein the characteristic amino acid sequence of the P53 antigen fragment is as shown in ID.1sequence; the characteristic amino acid sequence of the SOX2 antigen fragment is as shown in ID.2sequence; the characteristic amino acid sequence of the COPB1 antigen fragment is as shown in ID.3sequence; the characteristic amino acid sequence of the EFHD2 fragment is as shown in picture 4seeqeunce; the characteristic amino acid sequence of the EIF4G3 antigen fragment is as shown in ID.5seqeunce; the characteristic amino acid sequence of the PCNA antigen fragment is as shown in ID.6sequence. Early diagnosis or general investigation screening for suspected patients of lung cancer or high-risk population of lung cancer can be carried out extremely conveniently, quickly, noninvasively and efficiently.

Arteriosclerosis induces cerebral infarction and myocardial infarction. A multi-marker (a group of protein markers) that assesses the accurate pathogenesis of arteriosclerosis and enables the selection of an adequate treatment method for arteriosclerosis and prediction of the progression of arteriosclerosis, and an evaluation method for the diagnosis, prevention, and treatment of arteriosclerosis that uses said marker group as an indicator have been sought. The present invention relates to A method for evaluation of arteriosclerosis comprising the steps of (a) measuring the expression of von Willebrand factor and/or complement factor D in a sample derived from a subject, (b) measuring the expression of complement component C8 and/or vitamin K-dependent protein Z in the sample derived from the subject, and (c) evaluating arteriosclerosis in the subject on the basis of the results from (a) and (b).

Disclosed are methods for diagnosing breast cancer in a cell sample by detecting an increase in the levels of expression of protein markers in the cell sample as compared to the levels of expression of the same protein markers in a normal, nonneoplastic breast cell sample. Also disclosed is a device for diagnosis of cancer in a cell sample.